Polaris Genomics: Funding, Investors & Team (Oct 2026)
Polaris Genomics is utilizing molecular biomarkers to advance mental health diagnostics and novel therapeutics. The company identifies genomic biomarkers to aid in the development of psychiatric drugs and tools. Their ADAPT Platform™ compiles information on gene network pathways relevant to various neuropsychiatric conditions, such as anxiety, depression, and PTSD, through a targeted neuropsychiatric gene panel, deep analytics engine, and data repository. Specifically, ADAPT has successfully identified transcriptomic biomarkers for PTSD and introduced the PTS-ID™ clinical blood test for PTSD screening.
Polaris Genomics has raised $2.3M across 3 funding rounds on record, the most recent an undisclosed round of $250k announced in Aug 2025.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Polaris Genomics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Polaris Genomics Funding Rounds
Polaris Genomics raised $1.0M in an undisclosed round announced in May 2023.
7 months later, an undisclosed round of $1.0M was announced in Dec 2023.
1.7 years later, an undisclosed round of $250k was announced in Aug 2025.
Polaris Genomics Founders and Leadership Team
Contact details for the Polaris Genomics team: 1 of 1 has an email address on file.
Start 14-day free trial →Polaris Genomics Funding Compared to Other Biotechnology Startups
Polaris Genomics' latest round of $250k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Polaris Genomics in Biotechnology and Gaithersburg
Companies Similar to Polaris Genomics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Polaris Genomics Funding FAQs
What does Polaris Genomics do?
Polaris Genomics is utilizing molecular biomarkers to advance mental health diagnostics and novel therapeutics. The company identifies genomic biomarkers to aid in the development of psychiatric drugs and tools. Their ADAPT Platform™ compiles information on gene network pathways relevant to various neuropsychiatric conditions, such as anxiety, depression, and PTSD, through a targeted neuropsychiatric gene panel, deep analytics engine, and data repository. Specifically, ADAPT has successfully identified transcriptomic biomarkers for PTSD and introduced the PTS-ID™ clinical blood test for PTSD screening.
How much funding has Polaris Genomics raised?
Polaris Genomics has raised $2.3M across 3 rounds on record. The most recent is an undisclosed round of $250k announced in Aug 2025.
When did Polaris Genomics last raise funding?
Polaris Genomics' most recent funding round on record is an undisclosed round of $250k, announced in Aug 2025.
Who is the CEO of Polaris Genomics?
Charles Cathlin is listed as CEO at Polaris Genomics.
Where is Polaris Genomics headquartered?
Polaris Genomics is based in Gaithersburg, Maryland, United States.
How many employees does Polaris Genomics have?
Polaris Genomics is in the 11-50 employee band.
How does Polaris Genomics' funding compare to other Biotechnology startups?
Polaris Genomics' latest round of $250k is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Polaris Genomics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Polaris Genomics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.